Daniel George, MD
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Daniel George, MD sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Daniel George, MD: 6 sponsored US clinical trials, none currently recruiting.
Daniel George, MD sponsors 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hormone-refractory Prostate Cancer, with 1 trials.
Upper-quartile sponsor footprint
Daniel George, MD sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
6 total, page 1 of 1
A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer
NCT02963051
Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer
NCT03098836
Pazopanib, Docetaxel, Prednisone Prostate
NCT01385228
A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma
NCT00788060
RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer
NCT00629525
Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors
NCT00303732
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 2 |
Therapeutic Areas
How the Daniel George, MD early-phase archive is shaped
6 indexed studies, none listed as recruiting (0% open); 5 completed (83%).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Hormone-refractory Prostate Cancer (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Daniel George, MD: archived-pipeline peers nationwide
Peers matched on 6 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Daniel George, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 archived trials
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
Related
What to do with this Daniel George, MD page
6 registered trials is a research-attention snapshot, not an endorsement of Daniel George, MD or any single study.
- None of Daniel George, MD's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Hormone-refractory Prostate Cancer is the condition Daniel George, MD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hormone-refractory Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Daniel George, MD pipeline card: 6 registered trials from official public datasets.Report a data error.